BioPlus Acquisition Corp.

BioPlus Acquisition Corp., trading on Nasdaq under the ticker BIOS, is a blank-check company formed to pursue a business combination in the healthcare and life sciences sector. The company completed its initial public offering in 2022 and, as evidenced by its Form 425 filing dated August 16, 2023, was engaged in communications related to a proposed business combination transaction at that time. BioPlus targets opportunities across the broader biopharmaceutical and healthcare technology landscape, reflecting a continued investor appetite for sector-focused SPAC vehicles. For full deal terms, timeline updates, pipe details, and historical filing data on BioPlus Acquisition Corp. and hundreds of other SPACs, sign up for SpacDesk at spacdesk.com.